



Important Notice & Disclaimer

This presentation has been prepared by 4DMedical Limited (ACN 161 684 831, "Company" or "4DMedical"). This presentation contains summary information about the Company and its subsidiaries ("Group"), and the entities, businesses and assets they own and operate. Information regarding the Group and its activities are current as at **28 October 2021** unless otherwise stated, and the information remains subject to change without notice. This presentation contains general background information and does not purport to be complete. No attempt has been made to independently verify the information contained in this presentation.

Not an offer or financial product advice

The Company is not licensed to provide financial product advice. This presentation is not and should not be considered, and does not contain or purport to contain, an offer or an invitation to sell, or a solicitation of an offer to buy, directly or indirectly any securities, to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement or recommendation to enter into, any contract whatsoever relating to any securities. This presentation is for information purposes only and is not a prospectus, product disclosure statement, pathfinder document for the purposes of section 734(9) of the Australian Corporations Act 2001 (Cth) or other offer document under Australian law or the law of any other jurisdiction. This presentation does not constitute an invitation to apply for or purchase securities and does not include any application form for securities. This presentation does not constitute an advertisement for an offer or proposed offer of securities. Neither this presentation nor anything contained in it shall form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in, or refrain from engaging in, any transaction. Nothing in this presentation constitutes legal, financial, tax or other advice. Recipients of the presentation should conduct their own investigation, evaluation and analysis of the business and other data and information set out in the presentation.

Financial Data

All dollar values are in Australian dollars unless otherwise stated. Any financial data in this presentation is unaudited.

Past Performance

The operating and historical financial information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of the Company's views on its future performance or condition. Actual results could differ materially from those referred to in this presentation. You should note that past performance of the Group is not and cannot be relied upon as an indicator of (and provides no guidance as to) future Group performance.

Future Performance

This presentation contains certain "forward looking statements". The words "expect", "anticipate", "intend", "believe", "guidance", "propose", "goals", "targets", "aims", "outlook", "forecasts", "should", "would", "may", "will", "predict", and other similar expressions are intended to identify forward looking statements. Any indications of, and guidance on, future operating performance, earnings and financial position and performance are also forward-looking statements. Forward looking statements in this presentation include statements regarding the Company's future growth options, strategies and new products. Forward looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward looking statements, including projections, guidance on future operations, earnings and estimates (if any), are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. No representation is given that the assumptions upon which forward looking statements may be based are reasonable. This presentation contains statements that are subject to risk factors associated with the Group's industry. These forward-looking statements may be affected by a range of variables which could cause actual results or trends to differ materially, including but not limited to earnings, capital expenditure, cash flow and capital structure risks and general business risks. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including the Company). In particular, but without limitation, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this presentation will actually occur. Actual operations, results, performance or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Any forward-looking statements in this presentation speak only as of the date of this presentation. Subject to any continuing obligations under applicable law, the Company disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this presentation to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in this presentation will under any circumstances create an implication that there has been no change in the affairs of the Group since the date of this presentation.



2021 Annual General Meeting

28 October 2021

4DMedical Limited
ACN 161 684 831
ASX:4DX



2021 AGM Agenda

Opening & introductions

1. Procedural matters
2. Chairman's address
3. Managing Director & CEO's presentation
4. Formal business

Closing remarks





4DMedical Board of Directors & Company Secretary



Bruce Rathie

Non-Executive Director and
Chairman (independent)



Andreas Fouras PhD

Group Managing Director &
Chief Executive Officer



Lilian Bianchi

Non-Executive Director
(independent), Chair of the
Audit & Risk Committee



Dr Robert A. Figlin

Non-Executive Director
(independent)



Lusia Guthrie

Non-Executive Director
(independent)



Julian Sutton

Non-Executive Director



John Livingston

Non-Executive Director,
Chair of the Remuneration &
Nomination Committee



Charlene Stahr

Company Secretary

Procedural matters

Charlene Stahr,
Company Secretary

1



Procedural matters – how to vote

1

Click "**Get a Voting Card**" located at the top or bottom of the online platform

2

Enter your Shareholder Number and click "**Submit Details and Vote**"

3

Fill out your voting card for each item of business

4

Click "**Submit Vote**" or "**Submit Partial Vote**"



Procedural matters – how to ask a question (**online**)

1

Click “**Ask a Question**”
located at the top or bottom
of the online platform

2

Select the item of business
from the drop-down menu
and type your question into
the space provided

3

Once you have typed your
question, click “**Submit
Question**”



Procedural matters – how to ask a question **(phone)**

1

Join the Meeting via your landline or mobile phone.

From Australia:
1800 577 505

From overseas:
+61 2 9189 2002

2

When the Chairman calls for questions on each resolution, raise your hand by:

pressing *1 (asterisk 1)

You can lower your hand at any time by:

pressing *2 (asterisk 2)

3

Tell the moderator if your question(s) relate to an item of business or general business

4

When it's your time to ask your question, the moderator will introduce you to the Meeting and unmute your line. You can then start speaking

Chairman's address

Bruce Rathie,
Non-executive director & Chairman

2



FY21 financial summary

Cash reserves ▲ 860%
vs PY
\$80.88m

Operating costs ▲ 52%
vs PY
\$24.46m

Total income ▲ 71%
vs PY
\$5.77m

Loss after taxes ▼ 3%
vs PY
\$21.42m

Sales revenue ▼ 82%
vs PY
\$0.22m

Our people ▲ 132%
vs PY
95 staff

Other income ▲ 159%
vs PY
\$5.55m

- Significant cash reserve, with nil debt, following \$50.0m IPO in Aug 2020 and subsequent \$46.0m capital raising in Mar 2021 to support MRFF grant
- Sales revenue excludes US\$600k Permetium™ (preclinical) scanner sale announced 17 Jun 2021
- Other income includes \$4.1m R&D Tax Incentive credits and \$1.3m grant income, which comprises \$0.7m of initial MRFF funds received by ALHI (4DMedical subsidiary)
- Increased operating costs driven by continued investment in R&D and growing headcount
- Loss after tax includes \$2.63m of non-cash interest expense relating to convertible notes converted at the IPO
- Headcount more than doubled with notable expansion in the sales and distribution teams as commercialisation of XV LVAS™ accelerates

Managing Director & CEO presentation

Dr Andreas Fouras,
Group Managing Director & CEO


3



Global lung diagnostics market

~US\$31 billion global lung diagnostics market opportunity ripe for disruption

- Initial focus is on penetrating the U.S. and Australian markets representing a US\$13.7bn and US\$285m opportunity respectively
- Given the large market size, even low market penetration could lead to substantial revenue generation with high gross margin
- Approximately 99% of all lung diagnostics are made up of thoracic X-ray, thoracic CT, PFTs and nuclear medicine
- Current diagnostics trade off accuracy, sensitivity, cost and radiation exposure, while failing to provide comprehensive insight into the form and function of the patient's lungs





FY21 year in review

4DMedical has achieved several significant milestones during FY21 despite the challenges and uncertainties of the global COVID-19 pandemic

August 2020

Successful IPO and listing on ASX, raising \$50m of new capital

October 2020

AusIndustry approved Finding to receive tax credits for up to 43.5% of eligible overseas R&D expenditure

December 2020

First commercial use of XV LVAS™ to a patient based in Victoria, Australia

February 2021

4DMedical subsidiary, ALHI, awarded \$28.9m of funding under MRFF Frontier initiative

May 2021

Commenced first clinical trial for contrast-free Ventilation Perfusion (VQ) product

September 2020

Received TGA approval* for XV LVAS™ for all respiratory indications

November 2020

Secured research program in partnership with the University of Miami in the U.S.

January 2021

Secured first clinical pilot for XV LVAS™ at St. Joseph Hospital in the U.S.

March 2021

Streamlined access to U.S. Department of Defense & Veterans Affairs contracts via NASA SEWP approval

June 2021

Commenced XV LVAS™ clinical trial at Johns Hopkins, bringing the total number of active trials to eight



Commercialisation strategy

Clinical trials

(approx. 6+ months)



Research partners delivering the body of scientific evidence for clinical use

Who

Eminent researchers & leading medical institutes

Why

Diagnostics, treatment efficacy, monitoring, disease progression & more

Outcome:

- Scientific investigation into case applications
- Publishing medical manuscripts and presenting research to industry

Study design: Full scientific method per researcher

Commercial pilots

(approx. 3 weeks - 3 months)



Physicians gaining familiarity with XV Technology™ and insights for patient care

Who

GPs, respiratory specialists, imaging centres & hospitals

Why

Assess regional lung function for patient management

Outcome:

- Clinical familiarisation with XV Technology™
- Feasible new use of existing X-ray equipment (imaging centres)

Pilot design: Tiered per facility & physician interest



Clinical trials

4DMedical has eight clinical trials currently active driving awareness and education


		1	2	3	4	5	6	7	8
		Agreement executed	Study design approved	Budget approved	IRB approved	Patient recruitment	First imaging	Final imaging	Study complete
Site/indication	Product								
Cleveland Clinic Pulmonary Hypertension	VQ	●	●	●	●	5			
Duke University Lung Transplant	XV LVAS	●	●	●	●	●	6		
Vanderbilt University Constrictive Bronchiolitis	XV LVAS	●	●	●	●	●	6		
Johns Hopkins COPD	XV LVAS	●	●	●	●	●	6		
OHSU COPD	XV LVAS	●	●	●	●	●	6		
University of Miami COPD	XQ	●	●	●	●	●	6		
University of Miami COPD	XV LVAS	●	●	●	●	●	6		
Johns Hopkins Paediatric Cystic Fibrosis	XV LVAS	●	●	●	●	5			



Commercial pilot pipeline (AUS & USA)

4DMedical has rapidly established a strong commercial pilot pipeline comprising of capital city hospitals, national imaging centres and major GP practitioners

 Hospital Network  Veterans Affairs (VA) Hospital Network





Clinical case study (1)


Patient details

Male
45 years old

Clinical history

- Biopsy-proven silicosis
- Ex-smoker
- Right-sided chest discomfort with breathing

XV LVAS™ scan



Results

Tidal volume	▶	0.41L
Ventilation heterogeneity (%)	▶	63.2 total
Ventilation defect percentage (%)	▶	20.2%

Summary

- Patient history of silicosis and persistent discomfort on the right-side of chest
- Patient unable to complete a spirometry test due to breathing issues
- XV LVAS™ scan highlighted asymmetry in regional lung ventilation with relative reduction in ventilation on right side – corresponding with the patient's symptoms
- The patient and referring doctor gained additional insights into the patient's lung function



Clinical case study (2)


Patient details

Female
69 years old

Clinical history

- Past history of COVID 19
- Gastric Oesophageal Reflux Disease
- Recurrent chest infections

XV LVAS™ scan



Results


Tidal volume	▶	0.28L
Ventilation heterogeneity (%)	▶	91.9 total
Ventilation defect percentage (%)	▶	26.9%

Summary

- Patient history of COVID-19 infection and recurrent chest infections
- Patient completed a CT and XV LVAS™ scan that revealed a large hiatus hernia compressing adjacent areas of the lung
- The XV LVAS™ helped quantify a greater impact on ventilation in the in the left lower zone due to mass effect from the hernia (non-obstructive atelectasis)
- The impact of the hernia on ventilation was not fully appreciated on the CT scan



Staff hires by department



- Rapid expansion of our team in line with major business objectives, with staff growing 132% by end of FY21
- Focus on specialist expertise, including the Go-to-Market and Engineering teams which more than doubled in size
- A new Imaging Systems team was created to support the XVD Scanner™ project
- 95 total staff count at 30 June 2021 - 74 in Australia and 21 in the U.S., with 27% female staff in a male dominate industry
- Clinical and Medical Affairs also expanded significantly, to support clinical and pilot activities in the U.S. and Australia.



Outlook FY22

The Company is focused on the following activities:

1

Communication of XV Technology™ clinical trials results through publication in peer-reviewed medical journals and presentations at conferences to drive awareness, education and adoption at key opinion leading hospitals

2

Establishing commercial pilots with healthcare providers, identified by the Go-to-Market team, for day-to-day use to use of XV LVAS™ in their standard protocol/workflow

3

Conversion of commercial pilot partners, both existing and future, into paying customers of XV LVAS™

4

Continued investment into research and development of the Group's product pipeline, including the contrast free VQ product and XVD Scanner™, as well as XV LVAS™




Product pipeline

Each product is designed to expand applicable indications and market opportunity

	1 XV LVAS™ XV Lung Ventilation Analysis Software	2 VQ Ventilation Perfusion	3 XVD Scanner™ XV Dedicated Lung Scanner
Overview	Quantifies regional lung function at all locations in the lungs during active breathing FDA cleared and TGA approved	Evaluates airflow (ventilation) & blood flow (perfusion) in the lungs	The world's first dedicated lung function scanner enabling both XV LVAS™ and VQ outputs
Benefits	<ul style="list-style-type: none">▶ Low barrier to market entry, utilising existing fluoroscopy equipment▶ Lose dose, high sensitivity data	<ul style="list-style-type: none">▶ Easy to administer, faster & simpler than existing diagnostic technology▶ No contrast agent reduces patient harm	<ul style="list-style-type: none">▶ Leverages existing market uptake of XV Technology™▶ Reduced radiation dose, increased scanning throughput and broadened patient cohort
Use cases	<ul style="list-style-type: none">• Asthma• Chronic bronchitis• Cystic fibrosis• Lung transplant• Chronic obstructive pulmonary disease• Constrictive bronchiolitis	<ul style="list-style-type: none">• Pulmonary embolism• Pulmonary hypertension	<ul style="list-style-type: none">• Both XV LVAS and VQ indications in both adults and children
Competitor technology	X-ray (fluoroscopy) Computed Tomography (CT) Pulmonary Function Tests (PFTs)	Nuclear V/Q scan CT pulmonary angiogram	XV LVAS™ and VQ competitor devices Also X-ray (fluoroscopy)



Product milestones



Formal business

4



Item 1

Financial Report, Directors' Report & Auditor's Report

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

'To receive and consider the Financial Report of the Company and its controlled entities and the Reports of the Directors and Auditor for the year ended 30 June 2021.'

There is no vote on this item.



Item 2

Remuneration Report

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

'That the Remuneration Report, as contained in the Directors' Report for the year ended 30 June 2021, is adopted.'

**Note: the vote on this resolution is advisory only and does not bind the Directors or the Company.
An explanatory note for this item appears on page 11 of the Notice of Meeting.**



Item 2

Remuneration Report

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

'That the Remuneration Report, as contained in the Directors' Report for the year ended 30 June 2021, is adopted.'

Proxy votes

For	Open	Against	Abstained
59,962,963	2,610,079	2,185,415	724,757
92.59%	4.03%	3.37%	



Item 3

Re-election of Dr Robert A. Figlin

Joined Board: 9 December 2016



Background: Dr Figlin MD FACP is a Professor of Medicine and Biomedical Sciences and is the Steven Spielberg Family Chair in Hematology-Oncology, and Deputy Director of the Samuel Oschin Comprehensive Cancer Institute and Deputy Director of Integrated Oncology at Cedars-Sinai Medical Center in Los Angeles, California.

Dr Figlin received his medical degree from the Medical College of Pennsylvania. Dr Figlin completed his residency and chief residency in internal medicine at Cedars-Sinai Medical Center and a fellowship in hematology/oncology at the David Geffen School of Medicine at UCLA. He is an Emeritus Professor of Medicine and Urology at the David Geffen School of Medicine at UCLA.

Dr Figlin currently serves as Editor for Kidney Cancer Journal, and his studies have appeared in Clinical Cancer Research, Journal of Clinical Oncology, New England Journal of Medicine, Lancet, JNCI, Lancet Oncology, and Journal of Urology, among others. He has authored over 400 peer reviewed articles, more than 70 book chapters, and has published as editor multiple books on kidney cancer.

Dr Figlin is a nationally recognised leader in genitourinary and thoracic oncology whose research focuses on renal cell carcinoma and thoracic malignancies. He established and directs the Kidney Cancer Program at Cedars-Sinai Medical Center, which aims to understand the biology of kidney cancer and translate that knowledge into novel treatment approaches.



Item 3

Re-election of Dr Robert A. Figlin



To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

'That, for the purposes of clause 13.1 of the Company's constitution, ASX Listing Rule 14.5, and for all other purposes, Dr Robert A. Figlin, a non-executive director appointed on 9 December 2016, and being eligible, is re-elected as a director.'

Proxy votes

For	Open	Against	Abstained
119,445,619	2,643,090	6,165,598	5,018,333
93.13%	2.06%	4.81%	



Item 4

Non-executive Directors' Fees

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

'That for the purposes of clause 13.4 of the Company's constitution, ASX Listing Rule 10.17 and for all other purposes, the maximum aggregate director's fees that may be paid to the Directors of the Company as a whole (other than Executive Directors) be increased by \$250,000 per annum from \$500,000 per annum to \$750,000 per annum.'

An explanatory note for this item appears on page 12 of the Notice of Meeting.



Item 4

Non-executive Directors' Fees

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

'That for the purposes of clause 13.4 of the Company's constitution, ASX Listing Rule 10.17 and for all other purposes, the maximum aggregate director's fees that may be paid to the Directors of the Company as a whole (other than Executive Directors) be increased by \$250,000 per annum from \$500,000 per annum to \$750,000 per annum.'

Proxy votes

For	Open	Against	Abstained
59,033,856	2,610,773	3,762,392	1,133,875
90.26%	3.99%	5.75%	



Item 5

Grant of Options to the Managing Director & CEO

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

'That for the purposes of ASX Listing Rule 10.14, Chapter 2E of the Corporations Act 2001 (Cth), and for all other purposes, the grant of 701,719 options to Managing Director and CEO, Dr Andreas Fouras, under the 4DMedical Long Term Incentive Plan and on the terms described in the explanatory notes accompanying this notice, is approved.'

An explanatory note for this item appears on page 13 of the Notice of Meeting.



Item 5

Grant of Options to the Managing Director & CEO

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

'That for the purposes of ASX Listing Rule 10.14, Chapter 2E of the Corporations Act 2001 (Cth), and for all other purposes, the grant of 701,719 options to Managing Director and CEO, Dr Andreas Fouras, under the 4DMedical Long Term Incentive Plan and on the terms described in the explanatory notes accompanying this notice, is approved.'

Proxy votes

For	Open	Against	Abstained
61,696,073	2,608,993	2,494,595	784,979
92.36%	3.91%	3.73%	



Item 6(a)

Ratification of prior issue of shares – March 2021 placement (LR 7.1)

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

‘That for the purposes of ASX Listing Rule 7.4 and for all other purposes, shareholders approve and ratify the issue of 25,806,436 fully paid ordinary shares in the Company on 11 March 2021 to certain institutional and professional investors on the terms and conditions set out in the explanatory notes accompanying this notice.’

Item 6(b)

Ratification of prior issue of shares – April 2021 share purchase plan (LR 7.1)

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

‘That for the purposes of ASX Listing Rule 7.4 and for all other purposes, shareholders approve and ratify the issue of 3,870,954 fully paid ordinary shares in the Company on 7 April 2021 to certain shareholders of the Company on the terms and conditions set out in the explanatory notes accompanying this notice.’

An explanatory note for this item appears on page 15 of the Notice of Meeting.



Item 6(a)

Ratification of prior issue of shares – March 2021 placement (LR 7.1)

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

‘That for the purposes of ASX Listing Rule 7.4 and for all other purposes, shareholders approve and ratify the issue of 25,806,436 fully paid ordinary shares in the Company on 11 March 2021 to certain institutional and professional investors on the terms and conditions set out in the explanatory notes accompanying this notice.’

Proxy votes

For	Open	Against	Abstained
95,072,867	2,498,162	135,464	388,609
97.30%	2.56%	0.14%	



Item 6(b)

Ratification of prior issue of shares – April 2021 share purchase plan (LR 7.1)

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

'That for the purposes of ASX Listing Rule 7.4 and for all other purposes, shareholders approve and ratify the issue of 3,870,954 fully paid ordinary shares in the Company on 7 April 2021 to certain shareholders of the Company on the terms and conditions set out in the explanatory notes accompanying this notice.'

Proxy votes

For	Open	Against	Abstained
89,518,085	2,115,387	1,783,319	4,211,376
95.83%	2.26%	1.91%	



Item 7(a)

Ratification of prior issue of shares – Tax Exempt Employee Share Plan (LR 7.1)

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

‘That for the purposes of ASX Listing Rule 7.4 and for all other purposes, shareholders approve and ratify the issue of 52,042 fully paid ordinary shares in the Company on 29 June 2021 to certain employees of the 4DMedical group of companies, under the rules of the 4DMedical Tax Exempt Employee Share Plan and on the terms and conditions set out in the explanatory notes accompanying this notice.’

Item 7(b)

Approval in respect of the Tax Exempt Employee Share Plan

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

‘That for the purposes of ASX Listing Rule 7.1 and in accordance with ASX Listing Rule 7.2 Exception 13 and for all other purposes, the rules of the 4DMedical Tax Exempt Employee Share Plan (which are summarised in the Explanatory Notes accompanying this Notice) and the future issue of shares under that plan, be approved.’

An explanatory note for this item appears on page 17 of the Notice of Meeting.



Item 7(a)

Ratification of prior issue of shares – Tax Exempt Employee Share Plan (LR 7.1)

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

‘That for the purposes of ASX Listing Rule 7.4 and for all other purposes, shareholders approve and ratify the issue of 52,042 fully paid ordinary shares in the Company on 29 June 2021 to certain employees of the 4DMedical group of companies, under the rules of the 4DMedical Tax Exempt Employee Share Plan and on the terms and conditions set out in the explanatory notes accompanying this notice.’

Proxy votes

For	Open	Against	Abstained
60,278,043	2,030,274	352,763	95,718
96.20%	3.24%	0.56%	



Item 7(b)

Approval in respect of the Tax Exempt Employee Share Plan

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

'That for the purposes of ASX Listing Rule 7.1 and in accordance with ASX Listing Rule 7.2 Exception 13 and for all other purposes, the rules of the 4DMedical Tax Exempt Employee Share Plan (which are summarised in the Explanatory Notes accompanying this Notice) and the future issue of shares under that plan, be approved.'

Proxy votes

For	Open	Against	Abstained
58,540,897	2,030,274	2,080,332	105,295
93.44%	3.24%	3.32%	



Thank you

Contacts

► Corporate

Charlene Stahr

Company Secretary

companysecretary@4dmedical.com

► Investor Relations

Simon Hinsley

+61 401 809 653

shinsley@4dmedical.com

► Media

Matthew Wright

+61 451 896 420

matt@nwrcommunications.com.au

For more information, please visit

www.4DMedical.com